Second hepatectomy for recurrent colorectal liver metastasis: Analysis of preoperative prognostic factors

被引:49
作者
Ishiguro, Seiji
Akasu, Takayuki
Fujimoto, Yoshiya
Yamamoto, Junji
Sakamoto, Yoshihiro
Sano, Tsuyoshi
Shimada, Kazuaki
Kosuge, Tomoo
Yamamoto, Seiichiro
Fujita, Shin
Moriya, Yoshihiro
机构
[1] Natl Canc Ctr, Colorectal Surg Div, Chuo Ku, Tokyo 1040045, Japan
[2] Natl Canc Ctr, Hepatobiliary & Pancreat Surg Div, Chuo Ku, Tokyo 1040045, Japan
关键词
second hepatectomy; colorectal cancer; liver metastasis; prognostic factor; neoadjuvant chemotherapy;
D O I
10.1245/s10434-006-9067-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background: Second hepatectomy is a potentially curative treatment for patients with hepatic recurrence of colorectal cancer. However, there is still no consensus about the patient selection criteria for second hepatectomy under these circumstances, and the factors affecting prognosis after second hepatectomy remain uncertain. Methods: Clinicopathologic data for 111 consecutive patients with colorectal liver metastasis who underwent second hepatectomy at a single institution between 1985 and 2004, and for whom complete clinicopathologic reports were available, were subjected to univariate and multivariate analyses. Results: The morbidity and mortality rates were 14% and 0%, respectively, and the overall 5-year survival rate was 41%. Multivariate analysis revealed that synchronous resection for the first liver metastasis (hazard ratio, 1.8), more than three tumors at the second hepatectomy (1.9), and histopathological involvement of the hepatic vein and/or portal vein by the first liver metastasis (1.7) were independently associated with poor survival. We used these three risk factors to devise a preoperative model for predicting survival. The 5-year survival rates of patients without any risk factors, and with one, two, or three risk factors, were 62%, 38%, 19%, and 0%, respectively. Conclusions: Second hepatectomy is beneficial for patients without any risk factors. Before second hepatectomy, chemotherapy should be considered for patients with any of these risk factors, especially with two or three factors, in the adjuvant or neoadjuvant setting to prolong survival. These results need to be confirmed and validated in another data set or future prospective trial according to the scoring scheme we outline.
引用
收藏
页码:1579 / 1587
页数:9
相关论文
共 37 条
[1]
Adam R, 2001, ANN SURG ONCOL, V8, P347
[2]
Repeat hepatectomy for colorectal liver metastases [J].
Adam, R ;
Bismuth, H ;
Castaing, D ;
Waechter, F ;
Navarro, F ;
Abascal, A ;
Majno, P ;
Engerran, L .
ANNALS OF SURGERY, 1997, 225 (01) :51-60
[3]
Liver resection for colorectal metastases - The third hepatectomy [J].
Adam, R ;
Pascal, G ;
Azoulay, D ;
Tanaka, K ;
Castaing, D ;
Bismuth, H .
ANNALS OF SURGERY, 2003, 238 (06) :871-883
[4]
Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases [J].
Allen, PJ ;
Kemeny, N ;
Jarnagin, W ;
DeMatteo, R ;
Blumgart, L ;
Fong, Y .
JOURNAL OF GASTROINTESTINAL SURGERY, 2003, 7 (01) :109-115
[5]
Trends in long-term survival following liver resection for hepatic colorectal metastases [J].
Choti, MA ;
Sitzmann, JV ;
Tiburi, MF ;
Sumetchotimetha, W ;
Rangsin, R ;
Schulick, RD ;
Lillemoe, KD ;
Yeo, CJ ;
Cameron, JL .
ANNALS OF SURGERY, 2002, 235 (06) :759-765
[6]
REPEAT LIVER RESECTIONS FROM COLORECTAL METASTASIS [J].
FERNANDEZTRIGO, V ;
SHAMSA, F ;
SUGARBAKER, PH ;
HUGHES, KS ;
SCHEELE, J ;
STANGL, R ;
ELIAS, D ;
NAGOURNEY, DM ;
ILSTRUP, D ;
QUE, F ;
DAGRADI, A ;
NICOLI, N ;
SCHLAG, P ;
HOHENBERGER, P ;
STEVES, MA ;
VIDALJOVE, J ;
BERGAMASCHI, R ;
COPPA, GF ;
GAZZANIGA, M ;
CIFERRI, E ;
ANDERSON, R ;
HODGSON, WJB ;
NIMS, TA ;
CRUCITTI, F ;
MEYERS, WC ;
VANDEVELDE, CJH ;
ALDRETE, JS ;
KEMENY, MM ;
MARGARIT, C ;
MURIO, JE ;
CONNOLLY, DP ;
HERRERA, L .
SURGERY, 1995, 117 (03) :296-304
[7]
REPEAT HEPATIC RESECTIONS FOR METASTATIC COLORECTAL-CANCER [J].
FONG, Y ;
BLUMGART, LH ;
COHEN, A ;
FORTNER, J ;
BRENNAN, MF .
ANNALS OF SURGERY, 1994, 220 (05) :657-662
[8]
Liver resection for colorectal metastases [J].
Fong, YM ;
Cohen, AM ;
Fortner, JG ;
Enker, WE ;
Turnbull, AD ;
Coit, DG ;
Marrero, AM ;
Prasad, M ;
Blumgart, LH ;
Brennan, MF .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) :938-946
[9]
A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J].
Goldberg, RM ;
Sargent, DJ ;
Morton, RF ;
Fuchs, CS ;
Ramanathan, RK ;
Williamson, SK ;
Findlay, BP ;
Pitot, HC ;
Alberts, SR .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :23-30
[10]
Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy - Analysis of prognostic factors for 763 cases recorded at 18 institutions [J].
Kato, T ;
Yasui, K ;
Hirai, T ;
Kanemitsu, Y ;
Mori, T ;
Sugihara, K ;
Mochizuki, H ;
Yamamoto, J .
DISEASES OF THE COLON & RECTUM, 2003, 46 (10) :S22-S31